Source: Anais. Conference titles: Reunião Anual da Sociedade Brasileira de Química/RASBQ. Unidades: ICB, FCF
Assunto: LEUCEMIA
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. 2023, Anais.. São Paulo: Sociedade Brasileira de Química/SBQ, 2023. Disponível em: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf. Acesso em: 31 ago. 2024.APA
Carlos, J. A. E. G., Almeida, L. C. de, Lima, K., Tavares, M. T., Waitman, K. de B., Costa-Lotufo, L. V., et al. (2023). Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models. In Anais. São Paulo: Sociedade Brasileira de Química/SBQ. Recuperado de https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdfNLM
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Costa-Lotufo LV, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 ago. 31 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdfVancouver
Carlos JAEG, Almeida LC de, Lima K, Tavares MT, Waitman K de B, Costa-Lotufo LV, Parise Filho R, Machado Neto JA. Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models [Internet]. Anais. 2023 ;[citado 2024 ago. 31 ] Available from: https://www.sbq.org.br/46ra/anexos/anais-46rasbq.pdf